Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 pembrolizumab plus etoposide/platinum followed by pembrolizumab with or without olaparib maintenance in first-line extensive-stage small cell lung cancer
MOH_2019-11-03_007459Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in small cell lung cancer (SCLC) comparing Pembrolizumab + olaparib maintenance with Pembrolizumab + placebo maintenance (2 arms). Primary endpoints: Progression-free survival and Overall survival. Started Sep 2019; status: completed.
02
Drugs
pembrolizumabolaparib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on MOH_2019-11-03_007459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-11-03_007459.